LL-37 Research: A First-Time Researcher's FAQ

LL-37 is the 37-amino-acid C-terminal fragment released from the human cathelicidin precursor hCAP-18, and it appears in research catalogs because it is among the most studied host-defense peptides in the literature. For a business buying it for the first time, though, the decisive questions are not about the molecule. They are about identity, purity documentation, lot traceability, and whether a supplier will show you the lab work before you send money. Everything in this category is research use only — not a drug, not for human consumption, and not something to present to your customers as a therapy. What follows is the order a first-time buyer should work through, and why each step exists.

What LL-37 is and why it shows up in research catalogs

Cathelicidins are a family of host-defense peptides found across mammals. In humans, the precursor protein hCAP-18 is processed to release its active C-terminal fragment, which folds into a cationic, amphipathic alpha-helix — positively charged residues along one face, hydrophobic residues along the other. That architecture is the reason it is studied so heavily: research suggests the charge distribution governs how the peptide associates with lipid membranes, and studies also report signaling and chemotactic activity in cell-culture models of immune response. None of that is a claim about outcomes in people, and it should never be repeated to a customer as one.

The more commercially useful fact is structural. At 37 residues, LL-37 is long by solid-phase synthesis standards. Every residue added is another coupling cycle, and every cycle carries a small probability of a deletion or truncation sequence. Those failures accumulate multiplicatively, which is why a long chain routinely comes off the resin with a messier crude profile than a five- or seven-residue peptide. Its strong positive charge and hydrophobic face also make it prone to self-association during purification and to adsorbing onto glass and plastic surfaces. The practical consequence for a buyer: purity for this compound varies between suppliers far more than price does, and a supplier who cannot show you a chromatogram for the specific lot in your box is asking you to take the difficult part on faith.

Reading a certificate of analysis line by line

A certificate of analysis is the only object in this transaction that carries verifiable information. Treat it as the product and the vial as the packaging.

Start with the lot number. It must match the vial in hand, not a representative batch, not a sample document from last year. Then look for the actual HPLC chromatogram, not only a summary percentage. A trace shows you the main peak and what sits beside it; a bare number shows you a claim. Purity of 99%+ by HPLC is a reasonable benchmark to hold suppliers to, and it is the standard Real Peptides publishes across its catalog.

Next, identity. Purity says one thing dominates the sample; it does not say the dominant thing is the peptide you ordered. Mass spectrometry answers that by comparing observed mass against the theoretical mass for the sequence. Without it, you have a clean unknown.

Then understand the difference between purity and peptide content. Synthetic peptides are typically isolated as salts and retain counterions and bound water, so the net peptide mass in a vial can be meaningfully lower than gross fill weight. A COA that reports peptide content separately is being straight with you. One that reports only purity is not lying, but it is leaving out the number that determines what you actually received.

Finally, the contamination panels: endotoxin, bioburden, heavy metals, residual solvents, and moisture. These are the assays most often quietly skipped, because each one costs money per batch. Batch testing across multiple independent panels — Real Peptides runs a 7-panel test per batch — is the difference between a document that describes a product line and a document that describes your lot.

Questions to ask any supplier before the first order

The following exchange takes one email and tells you most of what you need to know.

Hidden pricing, paywalled certificates, and unverifiable in-house testing are the three industry practices that cost first-time buyers the most. None of them are difficult to detect if you ask before the first purchase order rather than after the third.

Storage, handling, and the records that protect you

Lyophilized peptides are stable under appropriate cold storage, but LL-37's physical properties make handling discipline more than a formality. Cationic, amphipathic peptides are prone to aggregation, and aggregated material behaves differently in assays than monomeric material — which means sloppy storage does not simply degrade inventory, it quietly corrupts the comparability of work done across different vials. Lyophilized powder is also hygroscopic; repeated exposure of a cold vial to room air invites condensation, and repeated freeze-thaw cycling is worth avoiding for the same reason.

On the business side, build a receiving process before the first shipment lands. Inspect on arrival, confirm the lot number against the published certificate, log the lot and receipt date, rotate stock first-in-first-out, and quarantine anything that arrives with compromised packaging or a missing document rather than shelving it and deciding later. Keep certificates filed against lot numbers, not against product names — if a question ever arises about a specific vial, the product name will not answer it and the lot number will.

Labeling matters equally. Research-use-only designation is not decoration; it is the frame the entire category sits inside, and your internal documentation, storage labels, and any customer-facing description should stay consistent with it. Compounds in this category are not approved drugs and are not intended for human consumption, and no packaging, invoice, or marketing copy should suggest otherwise.

Compliance questions that belong with your attorney

This section is informational and is not legal advice. What a business may purchase, hold, label, and resell in this category depends on business structure, jurisdiction, licensing posture, and how the business represents its products — and those are questions for your own counsel and, where relevant, your state board.

The useful thing to take away is not a conclusion but a list of questions to raise. How should research-use-only material be described in your catalog, on invoices, and in any advertising you run? What are the boundaries on marketing claims for products that are not approved drugs, and who reviews your copy against them? Does your business license or professional licensure affect what you can stock or resell, and does your state board have a position you need to confirm directly? What recordkeeping does your counsel want you to maintain on lots, suppliers, and certificates? Do your insurance and any professional obligations you carry interact with this category?

Anyone who answers those questions for you in a sales conversation — a supplier included — is guessing on your behalf. Get the framework from a lawyer who knows your setup, in writing, before volume grows to the point where changing course is expensive.

How wholesale pricing, tiers, and minimums generally work

Wholesale programs in this industry are usually built on volume tiers: unit pricing steps down as committed volume rises, sometimes per SKU and sometimes across the order. Minimum order quantities may be applied per item, per order, or per reorder cycle, and the structure matters more than the headline number, because a low per-order minimum spread across many SKUs can be harder to meet than a higher single-item minimum. Margins vary widely with volume, category, and how a business positions itself, and any supplier quoting you a specific margin figure is describing a hypothetical, not a commitment.

What you should expect is disclosure. A legitimate program tells a qualified applicant what the tiers are, where minimums sit, how reorders are handled, and what fulfillment looks like, during the application process rather than after a negotiation. Pricing that only appears after several calls is a structure designed around the seller's leverage, not the buyer's planning.

Also weigh lead time as a real cost. Inventory you cannot forecast forces you to hold more stock than you need, and long or unpredictable transit is the most common reason a growing catalog develops gaps.

What Real Peptides does differently

Real Peptides publishes the evidence rather than describing it. Every compound in the catalog is produced to 99%+ HPLC purity and undergoes 7-panel batch testing, and the resulting certificates of analysis are publicly verifiable — a prospective partner can read the lab results before applying, without an account, a sales call, or a separate fee. That is a deliberate inversion of the common practice of treating COAs as a post-sale document.

Fulfillment is US-based and ships in 5 to 7 days, which gives a buyer a planning window firm enough to forecast reorders against rather than a transit estimate that resets every shipment. The Wholesale Partner Program uses a 3-step application, so pricing tiers and terms are disclosed to qualified businesses as part of the process instead of being withheld as negotiating leverage.

Every compound is sold for research use only. Nothing in the catalog is an approved drug or intended for human consumption, and the program is structured for businesses that understand and maintain that distinction in their own operations.

Where a qualified buyer goes from here

If you operate a med spa, clinic, telehealth business, or reseller brand and you have worked through the documentation questions above, the next step is the Wholesale Partner Program application at Real Peptides — read a published certificate of analysis first, confirm it shows you what this article says it should, and apply once the evidence satisfies you rather than before.

Buyers assembling a first order often begin with the Popular Peptides range before moving into category-specific catalogs such as Gastrointestinal & Epithelial Research or Growth Factor & Tissue Signaling Research, and individual listings like KPV Peptide 10mg and BPC-157 10mg carry the same published lot documentation described above.